Analysis Of The Effect And Toxicity Of Locally Advanced NCLC Between IFI And ENI

Lung cancer is one of the most co㎜on malignant tumor, non-small cell lung cancer accounts for about 80% of cancer, only 20%～30% can resectable and locally advanced about 30%～40%, the regional and distant metastasis 40%. Now 5-year survival rate also only 25%. Non-small cell lung cancer(NSCLC), although radical surgery can obtain good effect, but a lot of patients with unresectable has belongs to the locally adanced cancer. Generally speaking, 64.3%士4.7% of non-small cell lung cancer patients will experience radiotherapy. However, radiation therapy did not appear the ideal result, many literature research shows that the failure mode of early NSCLC is happening local recurrence the after radical radiotherapy. In recent years the 3-dimensional conformal radiotherapy technology application makes accurate target areas, makes dose accurate, protects surrounding normal tissues , surgery, chemotherapy treatment, make the local control of lung cancer are short-term curative effect.Three-dimensional conformal radiotherapy is developed in the 1990s a new technology, it has been widely used in lung cancer radio- therapy. Three-dimensional conformal radiotherapy can improve local control by adding exposure dosage, And it can accurately calculate the target area surrounding normal tissues, reduce the normal tissue dose accept complications, it has been gradually replaced conventional ways of radiation, but if still take regular illuminate wild, irradiation range is too big, too much of the normal lung, esophageal and heart wrapped in irradiation range, causing surrounding normal tissues damage, the space is too little, improve dose local control also won't get bigger. Although 3-dimensional conformal radiotherapy technology for stage I non-small cell lung cancer illuminate doses of improving conditions, but with the traditional irradiation range to determine the clinical target area, radioactive pneumonia is one of the main factors, thus limited doses of radiation (i.e. by involving the wild only primary and short exposure > 10㎜ diameter of lymph node) can replace preventive or selectively lymph nodes (i.e. radiation fields including radiation in the primary, the ipsilateral hilar and subcarinal and long axons mediastinal lymphatic drainage area above, when the superior mediastinum are lymph node metastasis, including supraclavicular lymph drainage area, clinical research) becomes hot, also has achieved remarkable results, and confirmed the preventive lymph node dissection can improve local control and radiation exposure can improve the field and involving local exposure dosage, reduce the lung radioactive damnification, esophagus cardiac injury, damage and improve the comprehensive treatment, so as to improve the tolerability LeJu controlling rate. Therefore, we advocate for the operation stage I non-small cell lung cancer applications involving the wild radiation therapy technology.The combination chemotherapy aims to increase local stage I non-small cell lung cancer survival rates, the results also showed a radiotherapy or chemoth - erapy alone than in comparative advantage and the sequential chemotherapy and chemoradiation analysis on chemoradiation, although acute toxicity reaction will increase, but it shows a better curative effect and the sequential change compared with radiotherapy and chemotherapy, on the basis of platinum-based resection combined radiation can become the standard treatment for locally adanced NSCLC patients with locally advanced NSCLC, 5-year survival nearly 15%. In recent years the chemoradiation before induction chemotherapy and chemor- adiation after sustainingⅢchemotherapy of clinical research, confirmed the survival advantage, But still need further research. In recent years, radiotherapy combined targeted drugs also achieved satisfactory curative effect, but due to the limit, sample still need further clinical trials to confirm, as more and more new targeted drugs and radiation therapy, the application will be to cancer treatment brings new hope.Radiation as the primary non-small cell lung cancer treatments. Currently combination chemotherapy cannot surgery for locally advanced NSCLC standard treatment mode. Today's chest radiation pattern, including three-dimensional conformal radiotherapy technology can make the radiation dose and new application of anti-cancer drugs. New technology is developing, breathing radiotherapy door control and intensity-modulated technology can make more accurate target area, Stereotactic radiotherapy and proton therapy, surgical patients is early cannot handle.We retrospectively studied this radiation units in 50 cases of locally advanced non-small cell lung cancer,randomized field exposure group IFI and ENI, comparing the short-term curative effect and radioactive lung injury, the research results: IFI group CR 16.0 % (4/25), PR 52.0 % (13/25), SD 28 % (7/25),PD 4.0 % (1/25), Total effective rate (CR + PR) for 68.0%. ENI group CR 12.0 % (3/25), PR 48.0%(12/25), SD 28.0 % (7/25), PD 12.0 % (3/25), Total effective rate (CR + PR), 60.0%,P>0.05,for, no statistically significant differences.The comparative analysis, the rank and inspection of two groups of complete remission rate, the rate of disease progression ratio, illness, differences were not statistically significant. A, B two groups of patients I ~Ⅱlevel radioactive pneumonia was 16% of (4/25) and 48% (12/25),χ2=5.88,P<0.05,Ⅲ~Ⅳlevel radioactive pneumonia respectively 8%(2/25) (2) and 32%(8/25), two groups of comparisons,χ2=4.5,P<0.05. 1 year primary recurrence and ENI group chance for IF4.0%(1/25)and 8.0%(2/25)for (2), P>0.05,, no statistically significant differences, Wild illuminate area lymph node involvement (1 relapse are 4.0%) and 24.0% (6/25), P < 0.05, statistically significant, And two groups of preventive illuminate regional lymph nodes are 4.0% recurrence (1/25) and 8.0% for (2/25), P > 0.05, no statistically significant differences. IFI group, ENI group 1 year overall surial was 98.0% (24/25) and 88.0% (22/25), P> 0.05, no statistically significant differences, 2 years oerall surial respectively92.0%(23/25)and 68.0%(16/25)68.0% (16/25), P<0.05 statistically significant.StageⅢnon-small cell lung cancer therapy is the main challenge of local control problems, three-dimensional conformal radiotherapy technology application, IFI can improve local exposure dosage, reduce the normal tissue damage, and improve the local control and improve overall survival recently, therefore,IFI is completely feasible.